- within Food, Drugs, Healthcare and Life Sciences topic(s)
- with readers working within the Securities & Investment industries
- within Consumer Protection, Insurance and Technology topic(s)
This Stakeholders' Report provides a comprehensive analysis of key regulatory developments and legislative changes affecting Nigeria's health and pharmaceutical sector during the year 2025 (the "Report Period"). The report focuses on regulatory advancements that impact pharmaceutical manufacturers, distributors, healthcare providers, investors, and other stakeholders within the sector.
The year 2025 marked a transformative period characterized by unprecedented regulatory advancement, strategic infrastructure investments, and a renewed commitment to aligning domestic healthcare standards with international best practices. Nigeria's achievement as the first African nation to sustain the World Health Organisation's (WHO) Maturity Level 3 (ML3) status stands as a testament to years of systematic regulatory strengthening and institutional capacity building. This milestone, coupled with the gazetting of comprehensive pharmaceutical traceability regulations and the operationalization of specialized cancer treatment facilities, signals a maturing ecosystem where quality assurance, patient safety, and therapeutic access converge as policy priorities.
Open PDF to continue reading >>
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
